Healthcare distribution giant McKesson and private equity firm Clayton, Dubilier & Rice (CD&R) have agreed to acquire Option Care Health, a leading provider of home infusion services, for $32.05 per share. The all-cash deal values the company at approximately $5.8 billion, according to a statement from the companies.
Option Care Health delivers complex therapies—such as intravenous antibiotics, nutrition, and specialty drugs—directly to patients in their homes. The company has grown rapidly as more healthcare moves out of hospitals and into home settings, a trend accelerated by the pandemic and by insurers' push to lower costs.
Why the deal matters
For McKesson, the acquisition fits squarely into its strategy of expanding beyond traditional drug distribution into higher-margin healthcare services. McKesson already has a significant presence in specialty pharmaceuticals, and adding Option Care's home infusion network could create synergies in patient care and supply chain logistics.
For CD&R, the deal represents a continued bet on healthcare services, a sector that has attracted strong interest from private equity firms due to its steady cash flows and long-term growth prospects. The firm previously invested in other healthcare companies, and this acquisition gives it a platform in the fast-growing home care niche.
The $32.05-per-share price represents a premium to Option Care's recent trading levels, though the company's shares had been under pressure earlier this year amid concerns about reimbursement rates and competition. The deal is expected to close in the second half of 2025, subject to shareholder and regulatory approvals.
What it means for investors
For Option Care shareholders, the deal offers a clear exit at a set price, removing the uncertainty of quarterly earnings swings. For McKesson investors, the acquisition is a signal that the company is willing to deploy capital to strengthen its services arm, which could boost long-term growth but also adds integration risk.
Home infusion is a niche but growing part of the healthcare system. It allows patients to receive complex treatments at home rather than in a hospital, which can be more convenient and less expensive. As the population ages and chronic diseases become more common, demand for such services is likely to increase.
However, the sector is not without challenges. Reimbursement policies from Medicare and private insurers can change, and competition from other providers and hospital-owned programs is intense. McKesson and CD&R will need to navigate these headwinds while integrating Option Care's operations.
Elsewhere in healthcare, other companies made headlines. Stryker's announcement of a new CEO sent its shares lower, while a drug trial miss weighed on another biotech. These moves highlight the sector's sensitivity to leadership changes and clinical data.
For everyday investors, the takeaway is that healthcare remains a dynamic and deal-heavy sector. Mergers and acquisitions like this one can create value for shareholders of the target company, but they also carry risks for the acquirer. It's always wise to look beyond the headline price and consider how a deal fits into a company's broader strategy.
As the transaction moves toward completion, investors will be watching for any regulatory hurdles and for how McKesson plans to integrate Option Care. The deal is a reminder that in healthcare, the shift toward home-based care is not just a trend—it's becoming a core part of how medicine is delivered.
